Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sodium bicarbonate hepatic artery infusion plus anti-PD-1 versus HAIC plus anti-PD-1 in advanced hepatocellular carcinoma
ChiCTR2400087502Phase 2Not yet recruiting
- Sponsor
- Second Affiliated Hospital of Zhejiang University School of Medicine
- Start
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of sodium bicarbonate in hepatocellular carcinoma (HCC) (2 arms), sponsored by Second Affiliated Hospital of Zhejiang University School of Medicine. Primary endpoints: Overall survival and Objective response rate. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
sodium bicarbonate
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2400087502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400087502.